We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...

The United States market has shown robust performance with a 3.1% increase over the last week and a 24% rise over the past year, while earnings are projected to grow by 15% annually. In this favorable ...

Zai Lab (ZLAB) stock rose after positive trial data for its cervical cancer drug Tivdak and its plans to seek marketing ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

We feel now is a pretty good time to analyse Zai Lab Limited's ( NASDAQ:ZLAB ) business as it appears the company ...

Zai Lab (ZLAB) announced topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of ...

Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved SHANGHAI ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use ...

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab vedotin) in China after patients who took part in the Chinese segment ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug ...